Drugs / FDL169
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03527095 | Apr → Jun 2018 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1 | NCT03516331 | Mar → Aug 2018 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1 | NCT03424252 | Dec 2017 → Jan 2018 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1 | NCT03093714 | Aug 2017 → Apr 2018 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1 | NCT02680418 | Dec 2015 → Feb 2016 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1 | NCT02359357 | Jan 2015 → Mar 2016 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03756922 | Nov 2018 → Feb 2020 | cystic fibrosis | Flatley Discovery Lab LLC | Suspended | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02767297 | Apr → Oct 2016 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FDL169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03093714 ↗ |
| Known as | Cftr corrector 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095180 ↗ |
| Action | Restore | “CFTR corrector” NCT03756922 ↗ |
| Modality | Small molecule | — CHEMBL5095180 ↗ |
| Route | Oral | “single oral administrations of FDL169” NCT02359357 ↗ |
| Target | CFTR | “Cystic Fibrosis Transmembrane Regulator (CFTR) corrector” NCT03424252 ↗ |